Jonathan Miller
Stock Analyst at Evercore ISI Group
(n/a)
# 4,820
Out of 5,117 analysts
6
Total ratings
n/a
Success rate
-40.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Reinstates: Outperform | $13 | $5.18 | +150.97% | 1 | Nov 26, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $9.37 | -14.62% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $2.14 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $10.50 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $3.89 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $20.89 | - | 1 | Jan 6, 2021 |
Aura Biosciences
Nov 26, 2025
Reinstates: Outperform
Price Target: $13
Current: $5.18
Upside: +150.97%
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $9.37
Upside: -14.62%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.14
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.50
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.89
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.89
Upside: -